Fosfomycin intravenous - Zavante Therapeutics

Next Previous
Drug Profile

Fosfomycin intravenous - Zavante Therapeutics

Alternative Names: Fosfomycin disodium; ZOLYD; ZTI-01

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zavante Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • No development reported Pseudomonal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pseudomonal-infections(In volunteers) in USA (IV, Infusion)
  • 08 Oct 2017 Pharmacodynamics data from a preclinical study in Pseudomonal infections presented at the IDWeek 2017
  • 04 Oct 2017 Additional efficacy data from the phase II/III ZEUS trial in Urinary tract infections presented at the IDWeek 2017 (IDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top